Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Jan 20, 2022

SELL
$10.83 - $18.41 $2.58 Million - $4.38 Million
-237,988 Closed
0 $0
Q3 2021

Nov 03, 2021

BUY
$13.07 - $18.84 $6,299 - $9,080
482 Added 0.2%
237,988 $4.27 Million
Q2 2021

Jul 21, 2021

SELL
$16.52 - $20.4 $4,675 - $5,773
-283 Reduced 0.12%
237,506 $4.08 Million
Q1 2021

Apr 15, 2021

BUY
$16.56 - $25.46 $65,395 - $100,541
3,949 Added 1.69%
237,789 $4.76 Million
Q4 2020

Jan 26, 2021

BUY
$15.77 - $19.03 $4,384 - $5,290
278 Added 0.12%
233,840 $3.98 Million
Q3 2020

Oct 20, 2020

BUY
$16.59 - $24.79 $21,699 - $32,425
1,308 Added 0.56%
233,562 $3.88 Million
Q2 2020

Jul 23, 2020

BUY
$16.86 - $23.44 $53,530 - $74,422
3,175 Added 1.39%
232,254 $5.38 Million
Q4 2019

Jan 28, 2020

SELL
$15.87 - $23.12 $2.6 Million - $3.78 Million
-163,693 Reduced 41.68%
229,079 $4.95 Million
Q3 2019

Oct 30, 2019

BUY
$16.91 - $36.27 $5.27 Million - $11.3 Million
311,483 Added 383.18%
392,772 $7.15 Million
Q2 2019

Jul 09, 2019

SELL
$31.0 - $36.3 $4.38 Million - $5.13 Million
-141,279 Reduced 63.48%
81,289 $2.89 Million
Q1 2019

Apr 15, 2019

SELL
$31.58 - $46.35 $138,288 - $202,966
-4,379 Reduced 1.93%
222,568 $7.48 Million
Q4 2018

Jan 10, 2019

BUY
$30.43 - $56.65 $1.49 Million - $2.77 Million
48,859 Added 27.44%
226,947 $7.46 Million
Q3 2018

Oct 24, 2018

BUY
$46.46 - $68.49 $1.56 Million - $2.3 Million
33,562 Added 23.22%
178,088 $10.9 Million
Q2 2018

Jul 17, 2018

BUY
$46.25 - $104.45 $3.13 Million - $7.07 Million
67,649 Added 88.0%
144,526 $7.06 Million
Q1 2018

Apr 27, 2018

BUY
$57.4 - $108.44 $4.41 Million - $8.34 Million
76,877 New
76,877 $8.17 Million

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $219M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Retirement Systems Of Alabama Portfolio

Follow Retirement Systems Of Alabama and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Retirement Systems Of Alabama, based on Form 13F filings with the SEC.

News

Stay updated on Retirement Systems Of Alabama with notifications on news.